Arrowhead Pharmaceuticals Inc. [ARWR] Chief Discovery/Trans Medicine makes an insider purchase of 7,940 shares worth 0.29 million.

Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Arrowhead Pharmaceuticals Inc. shares valued at $292,904 were sold by Hamilton James C on Jan 12. At $36.89 per share, Hamilton James C sold 7,940 shares. The insider’s holdings dropped to 210,851 shares worth approximately $6.77 million following the completion of this transaction.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

Also, Vakiener Victoria sold 4,720 shares, netting a total of over 179,813 in proceeds. Following the sale of shares at $38.10 each, the insider now holds 32,001 shares.

Before that, Waddill William D. had sold 3,934 shares from its account. In a trade valued at $149,759, the Director traded Arrowhead Pharmaceuticals Inc. shares for $38.07 each. Upon closing the transaction, the insider’s holdings decreased to 3,934 shares, worth approximately $1.54 million.

As published in their initiating research note from BofA Securities on December 04, 2023, Arrowhead Pharmaceuticals Inc. [ARWR] has been a Buy and the price target has been revised to $29.

Analyzing ARWR Stock Performance

During the last five days, there has been a drop of approximately -2.16%. Over the course of the year, Arrowhead Pharmaceuticals Inc. shares have jumped approximately 4.90%. Shares of the company reached a 52-week high of $39.83 on 01/10/24 and a 52-week low of $29.65 on 01/02/24. A 50-day SMA is recorded $30.44, while a 200-day SMA reached $31.12. Nevertheless, trading volume fell to 0.86 million shares from 0.75 million shares the previous day.

Support And Resistance Levels for Arrowhead Pharmaceuticals Inc. (ARWR)

According to the 24-hour chart, there is a support level at 31.47, which, if violated, would cause prices to drop to 30.85. In the upper region, resistance lies at 33.04. The next price resistance is at 33.99. RSI (Relative Strength Index) is 47.46 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.83, which suggests the price will decrease in the coming days. Percent R is at 96.00%, indicating bearish price movement. Stochastics %K at buying indicates that the stock is to be held.

Is Arrowhead Pharmaceuticals Inc. subject to short interest?

Stocks of Arrowhead Pharmaceuticals Inc. saw a sharp rise in short interest on Jan 11, 2024 jumping by 1.13 million shares to 8.87 million. Data from Yahoo Finance shows that the short interest on Dec 14, 2023 was 7.74 million shares. A jump of 12.74% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 4.36 of the overall float, the days-to-cover ratio (short ratio) jumped to 4.36.

Leave a Reply

Your email address will not be published. Required fields are marked *

Most Popular